These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 26199396)

  • 61. Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis.
    Reinhardt A; Prinz I
    Front Immunol; 2018; 9():885. PubMed ID: 29922283
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis.
    Ciccia F; Guggino G; Rizzo A; Saieva L; Peralta S; Giardina A; Cannizzaro A; Sireci G; De Leo G; Alessandro R; Triolo G
    Ann Rheum Dis; 2015 Sep; 74(9):1739-47. PubMed ID: 25902790
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Spreading spondyloarthritis: are ILCs cytokine shuttles from base camp gut?
    Neerinckx B; Elewaut D; Lories RJ
    Ann Rheum Dis; 2015 Sep; 74(9):1633-5. PubMed ID: 26199396
    [No Abstract]   [Full Text] [Related]  

  • 64. Gut microbes, immunity, and spondyloarthritis.
    Stoll ML
    Clin Immunol; 2015 Aug; 159(2):134-42. PubMed ID: 25967460
    [TBL] [Abstract][Full Text] [Related]  

  • 65. IL-23/IL-17 axis in spondyloarthritis-bench to bedside.
    Raychaudhuri SP; Raychaudhuri SK
    Clin Rheumatol; 2016 Jun; 35(6):1437-41. PubMed ID: 27075462
    [TBL] [Abstract][Full Text] [Related]  

  • 66. IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?
    Baeten D; Adamopoulos IE
    Front Immunol; 2020; 11():623874. PubMed ID: 33679714
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The interleukin-23/interleukin-17 axis in spondyloarthritis.
    Layh-Schmitt G; Colbert RA
    Curr Opin Rheumatol; 2008 Jul; 20(4):392-7. PubMed ID: 18525350
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treating to target in axial spondyloarthritis: defining the target and the arrow.
    Wendling D
    Expert Rev Clin Immunol; 2015 Jun; 11(6):691-3. PubMed ID: 25905676
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Imaging of the seronegative spondyloarthopathies.
    Amrami KK
    Radiol Clin North Am; 2012 Jul; 50(4):841-54. PubMed ID: 22643398
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inflammatory pathways in spondyloarthritis.
    Hreggvidsdottir HS; Noordenbos T; Baeten DL
    Mol Immunol; 2014 Jan; 57(1):28-37. PubMed ID: 23969080
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The critical role of interleukin-23 in spondyloarthropathy.
    Sherlock JP; Buckley CD; Cua DJ
    Mol Immunol; 2014 Jan; 57(1):38-43. PubMed ID: 23910729
    [TBL] [Abstract][Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.